Legend Biotech (LEGN) Cash from Operations (2019 - 2026)
Legend Biotech's (LEGN) quarterly Cash from Operations came in at 85100000.0 in Q1 2026, up 17.86% YoY from 72206060.61 in Q1 2025, and down 597.54% on a QoQ basis from 12200000.0 in Q4 2025.
Powered by 
Analysis
Legend Biotech (LEGN) Cash from Operations (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Cash from Operations data on file, last reported at 85100000.0 in Q1 2026.
- Quarterly Cash from Operations rose 17.86% year-over-year to 85100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81695000.0 (up 68.96% YoY) and the FY2025 annual result came in at 100200000.0, up 30.42% from the prior year.
- Cash from Operations declined to 85100000.0 in Q1 2026, from 12200000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 28801000.0 in Q3 2025 to a low of 139215000.0 in Q1 2023.
- A 5-year average of 54347470.59 and a median of 72112000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 13084.86% — and 2025, when it soared 137.99%.
- Tracing LEGN's Cash from Operations over 5 years: stood at 49742000.0 in 2022, then slumped by 92.28% to 95645000.0 in 2023, then rose by 14.16% to 82100000.0 in 2024, then surged by 85.14% to 12200000.0 in 2025, then slumped by 597.54% to 85100000.0 in 2026.
- The last three Cash from Operations figures came in at 85100000.0 (Q1 2026), 12200000.0 (Q4 2025), and 28801000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -20.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.90 Mn |
| Mar 31, 2026 | -85.10 Mn |
| Dec 31, 2025 | -12.20 Mn |
| Sep 30, 2025 | 28.81 Mn |
| Jun 30, 2025 | -13.20 Mn |
| Mar 31, 2025 | -103.60 Mn |
| Dec 31, 2024 | -82.10 Mn |
| Sep 30, 2024 | -75.82 Mn |
| Jun 30, 2024 | -1.65 Mn |
| Mar 31, 2024 | 15.52 Mn |
| Dec 31, 2023 | -95.65 Mn |
| Sep 30, 2023 | -60.85 Mn |
| Jun 30, 2023 | -97.57 Mn |
| Mar 31, 2023 | -139.22 Mn |
| Dec 31, 2022 | -49.74 Mn |
| Sep 30, 2022 | -72.11 Mn |
| Jun 30, 2022 | -740,000.00 |
| Mar 31, 2022 | -78.69 Mn |
| Dec 31, 2021 | -198.47 Mn |
| Sep 30, 2021 | -44.59 Mn |